Business Description
Pro Medicus Ltd
ISIN : US74276V1035
Share Class Description:
PMDIY: ADRTotal Employee Number:
75Description
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 87.82 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 148.89 | |||||
Beneish M-Score | -2.11 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31.6 | |||||
3-Year EBITDA Growth Rate | 33.2 | |||||
3-Year EPS without NRI Growth Rate | 37.3 | |||||
3-Year FCF Growth Rate | 25.4 | |||||
3-Year Book Growth Rate | 36.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 23.81 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 64.88 | |||||
9-Day RSI | 66.41 | |||||
14-Day RSI | 65.89 | |||||
3-1 Month Momentum % | 24.26 | |||||
6-1 Month Momentum % | -40.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.22 | |||||
Quick Ratio | 6.22 | |||||
Cash Ratio | 4.55 | |||||
Days Inventory | 96.27 | |||||
Days Sales Outstanding | 97.72 | |||||
Days Payable | 11064.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.35 | |||||
Dividend Payout Ratio | 0.25 | |||||
3-Year Dividend Growth Rate | 37.7 | |||||
Forward Dividend Yield % | 0.35 | |||||
5-Year Yield-on-Cost % | 1.63 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.38 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.87 | |||||
Operating Margin % | 74.16 | |||||
Net Margin % | 97.59 | |||||
EBITDA Margin % | 77.38 | |||||
FCF Margin % | 50.1 | |||||
OCF Margin % | 53.15 | |||||
ROE % | 81.1 | |||||
ROA % | 60.34 | |||||
ROIC % | 73.76 | |||||
3-Year ROIIC % | 121.31 | |||||
ROC (Joel Greenblatt) % | 567.73 | |||||
ROCE % | 51.42 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 84.21 | |||||
Forward PE Ratio | 94.4 | |||||
PE Ratio without NRI | 84.21 | |||||
Shiller PE Ratio | 449.69 | |||||
Price-to-Owner-Earnings | 170.93 | |||||
PEG Ratio | 2.46 | |||||
PS Ratio | 82.19 | |||||
PB Ratio | 50.76 | |||||
Price-to-Tangible-Book | 54.33 | |||||
Price-to-Free-Cash-Flow | 164.1 | |||||
Price-to-Operating-Cash-Flow | 154.69 | |||||
EV-to-EBIT | 109.4 | |||||
EV-to-EBITDA | 104.85 | |||||
EV-to-Revenue | 81.13 | |||||
EV-to-Forward-Revenue | 56.51 | |||||
EV-to-FCF | 162.01 | |||||
Price-to-GF-Value | 0.77 | |||||
Price-to-Projected-FCF | 20.38 | |||||
Price-to-DCF (Earnings Based) | 2.64 | |||||
Price-to-DCF (FCF Based) | 5.18 | |||||
Price-to-Median-PS-Value | 1.56 | |||||
Price-to-Peter-Lynch-Fair-Value | 6.87 | |||||
Price-to-Graham-Number | 14.22 | |||||
| Price-to-Net-Current-Asset-Value | 122.25 | |||||
| Price-to-Net-Cash | 244.5 | |||||
Earnings Yield (Greenblatt) % | 0.91 | |||||
FCF Yield % | 0.61 | |||||
Forward Rate of Return (Yacktman) % | 20.29 |
Pro Medicus Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pro Medicus Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-24 10:00 | In 150 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-14 11:00 | In 48 days | ||
| Annual report for 2026 | 2026-08-14 | In 47 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-14 | In 47 days | ||
| USD 0.045286 Cash Dividend | 2026-02-27 | 18.36 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-12 | 23.76 (+0.00%) | ||
| General meeting for 2025 | 2025-11-24 10:00 | 29.78 (+0.00%) | ||
| USD 0.039450 Cash Dividend | 2025-09-04 | 37.88 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-08-14 11:00 | 37.85 (+0.00%) | ||
| Annual report for 2025 | 2025-08-14 | 37.85 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:PMDIY
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Visage Highlights One Platform AI-Optimized at SIIM26 | 2026-06-08 | ||
| Visage Elevates AI Optimized Enterprise Imaging at HIMSS26 | 2026-03-10 | ||
| Visage Propels AI Optimized Enterprise Imaging at RSNA 2025 | 2025-11-19 | ||
| Visage Achieves Authority to Operate (ATO) from the U.S. Department of Veterans Affairs | 2025-09-04 | ||
| Visage Transforms Imaging to the Cloud at RSNA 2024 | 2024-11-12 | ||
| Visage Leads with CloudPACS at SIIM 2024 | 2024-06-25 | ||
| Visage Soars with CloudPACS at RSNA 2023 | 2023-11-14 | ||
| Visage 7 Named Best in KLAS 2023 | 2023-02-08 | ||
| Visage Announces Support of Amazon HealthLake Imaging | 2022-11-27 | ||
| Visage Leads with CloudPACS at RSNA 2022 | 2022-11-14 |
Articles on Pro Medicus Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers